Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy 
Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
US Judge Dismisses Gautam Adani Criminal Charges 
Oil Prices Rise as Hormuz Tensions Threaten Global Supply 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Oil, Gold Rise as Geopolitical Risks Grip Markets Ahead of U.S. CPI 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Airbus Joins Air India A320 Altitude Drop Probe 
U.S. Stock Futures Flat Ahead of July CPI Data 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Samsung Biologics Co. was revealed to have won a new CMO contract deal with Pfizer Ireland Pharmaceuticals. The order is said to be worth $183 million, which is equivalent to 15.4% of Samsung Biologic's total sales profits in 2021.
Samsung Biologics is currently the no. 1 contract drug maker in the world based on production capacity. It has bagged this huge contract manufacturing organization (CMO) order from the Ireland unit of Pfizer Inc. the deal just raised expectations that the biotech division of Samsung Group's orders for this year will reach a new record high.
As per The Korea Economic Daily, Samsung Biologics announced its new CMO order through a regulatory filing on Thursday, March 2. Although this was only revealed now, the actual order was made by Pfizer Ireland Pharmaceuticals Ringaskiddy on Feb. 28.
Then again, the biotech firm did not mention the name of the medicine that it will make for Pfizer. It was stated in the contract that the manufacturing will run from Feb. 20, 2023, to Dec. 31, 2029.
In any case, this is the first time that Samsung Biologics or any Korean company has signed a CMO deal with the New York-headquartered pharmaceutical and biotech firm. Korea Joongang Daily reported with the latest business announcement, Samsung Biologics now boasts of having seven of the world's top 10 largest pharmaceutical firms as clients.
The Korean biotech company was established in 2011, and it has started partial operation of its fourth factory in Songdo, Incheon, just recently. This facility will have the capacity to produce 240,000 liters when it goes into full operation in June. This is said to be the largest single pharma production facility in the world.
Meanwhile, Samsung Biologics is investing another KRW 7.5 trillion or about $5.7 billion to build four new plants inside a manufacturing complex near its existing plants in the Songdo region.
